


Company

Marinomed Biotech AG was founded in 2006 and is a biopharmaceutical company focused on the discovery and development of clinically meaningful therapies for diseases in the field of virology and immunology. Our business model is based on what we do best: research of innovative therapeutic approaches, preclinical and clinical drug development and out-licensing. In successful collaborations, we use what our pharmaceutical partners do best: clinical development, regulatory affairs and commercialization.




Our patent-protected and marketed Carragelose® products for the treatment of viral respiratory infections have already been partnered in over 40 countries. We are also developing antiviral drugs for serious viral infectious diseases based on the virus-blocking active ingredient iota-carrageenan.



Based on the Marinosolv® technology, which improves the solubility of active pharmaceutical ingredients, we want to sustainably improve therapies for autoreactive immune diseases. Our flagship product Budesolv/MAM-1004-1 for the treatment of allergic rhinitis is already being prepared for approval. Further therapies for the treatment of diseases of the anterior eye and the gastrointestinal tract are in development.

Marinomed's vision is to sustainably improve the lives of patients suffering from viral infectious diseases or autoreactive immune diseases with inadequate treatment options. Since our founding, we have been able to successfully demonstrate the great potential of our high-performance technologies.

Pipeline



Share

Marinomed Biotech AG has been listed on the Vienna Stock Exchange (VSE: MARI) since 2019. The shares are listed in the Prime Market segment and included in the ATX Prime Index.

Selected key financial figures

| In EUR mio. | 2021 | 2020 | 2019 |
|-------------------|-------|-------|-------|
| Revenues | 11.63 | 8.12 | 6.14 |
| EBIT | -4.14 | -5.82 | -6.21 |
| Loss for the year | -5.89 | -6.01 | -7.22 |
| R&D expenses | 7.50 | 5.94 | 4.78 |

Financial calendar

| | |
|----------|------------------------|
| 13.04.22 | Annual Report 2021 |
| 23.05.22 | Results Q1 2022 |
| 15.06.22 | Annual General Meeting |
| 25.08.22 | Results H1 2022 |
| 21.11.22 | Results Q3 2022 |

Sustainability

Sustainable management is part of Marinomed's corporate strategy. The focus of our company is to improve the health of patients in the long term. We want to achieve this by developing innovative, more effective and more targeted therapies. Our sustainability goals also include the protection of the environment and climate as well as diversity, the search for strong partnerships and much more.



Contact

Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg, Österreich

Tel.: +43 2262 90300
www.marinomed.com
ir@marinomed.com
pr@marinomed.com